This theory should warrant a future study with a higher dose intensity of codrituzumab in an HCC population with high GPC3 IHC (1+, 2+ and 3+) along with CD16 MESF above the 25th percentile (234K MESF in our established assay) at baseline to establish the therapeutic benefit of codrituzumab in HCC. This evidence concerns the gene GPC3 and hepatocellular carcinoma.